Short Report

The M694V mutation in Armenian-Americans: a 10-year retrospective study of MEFV mutation testing for familial Mediterranean fever at UCLA

Familial Mediterranean fever (FMF), inherited in an autosomal recessive manner, is a systemic auto-inflammatory disorder characterized by recurrent attacks of fever with peritonitis, pleuritis, synovitis and erysipelas rash. The marenostrin-encoding fever (MEFV) gene, located on chromosome 16p13.3, is the only gene in which mutations are currently known to cause FMF. To correlate specific genotypes with adverse phenotypes of affected populations residing in the Western United States, a retrospective case series review was conducted of all MEFV gene mutation testing completed at UCLA Clinical Molecular Diagnostic Laboratory between February 2002 and February 2012, followed by clinical chart review of all subjects who either have a single or double mutation. All 12 common mutations in the MEFV gene were analyzed and the M694V variant was found to be associated with an adverse FMF clinical outcome in the Armenian-American population, manifested by earlier onset of disease, increased severity of disease, and renal amyloidosis.

Conflict of interest
Each author declares no conflict of interest.

Key words: Armenian – clinical laboratory testing – Familial Mediterranean Fever – MEFV – molecular diagnostics

Corresponding author: Wayne W. Grody, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, Los Angeles, CA 90095, USA. Tel.: +310 825 5648; fax: +310 206 4255; e-mail: wgrody@mednet.ucla.edu

Received 3 August 2012, revised and accepted for publication 25 September 2012
Familial Mediterranean fever (FMF), inherited in an autosomal recessive manner, is a systemic auto-inflammatory disorder (1). FMF type I is characterized by recurrent short episodes of inflammation and serositis, including fever, peritonitis, synovitis, pleuritis, with amyloidosis being the most severe complication. FMF type II is characterized by amyloidosis as the first clinical manifestation of the disease in an otherwise asymptomatic individual (2). The marenostrin-encoding fever (MEFV, MIM#: 608107) gene, located on chromosome 16p13.3, is the only gene in which mutations are currently known to cause FMF (3–8). Five founder mutations, namely p.Met694Val, p.Met694Ile, p.Val726Ala, p.Met680Ile in exon 10 and p.Glu148Gln in exon 2, are responsible for the majority of mutations in the Mediterranean population of patients with classic presentation of FMF (9). FMF predominantly affects populations from the Mediterranean region, such as Armenians, non-Ashkenazi Jews, Turks, Persians and Arabs, with carrier rates as high as one in seven in particular populations (1, 10–12). However, occurrence of FMF has also been observed in individuals with non-Mediterranean ancestries, such as Japanese, Chinese, European, and South American populations (13, 14).

Molecular genetic diagnostic testing is usually used to provide a confirmation of the FMF diagnosis when the clinical presentation of FMF is less typical. In most individuals with symptoms of FMF, targeted mutation analysis of the common MEFV mutations identifies double (homozygous or compound heterozygous) mutations, confirming the diagnosis. It is not uncommon to detect no mutant allele or only a single-mutant allele, particularly in patients with non-classic FMF or patients with mild, variable or atypical clinical presentations. Sequence analysis of the entire coding region may then be warranted; however, even that approach will not always yield the second mutation (15). Clinicians have accepted the molecular test as supportive of FMF and presume that the second mutation may not be detected possibly because of rarity or location outside the analyzed gene regions (16). There had been previous reports of certain genotypes correlating with adverse phenotypes in the populations around the Mediterranean region (10, 12, 14); however, it was not known whether this was true for affected populations residing in the Western United States. Thus, a retrospective case series review was conducted of all MEFV gene mutation testing completed at UCLA Clinical Molecular Diagnostic Laboratory between February 2002 and February 2012, followed by clinical chart review of all subjects who either have a single or double mutation.

Materials and methods
All data were collected after approval by the University of California, Los Angeles Institutional Review Board (IRB# 11–00517).

MEFV mutation testing
The detection of the 12 MEFV mutations in exons 2, 5, and 10 – E148Q, P369S, F479L, M680I (G/C), M680I (G/A), I692del, M694V, M694I, K695R, V726A, A744S, R761H – was conducted using the ViennaLab FMF StripAssay kit (ViennaLab Dignostics GmbH, Vienna, Austria) (1). Detection involves multiplex polymerase chain reaction (PCR) amplifying four products with biotinylated primers, reverse hybridization of PCR products to test strips containing oligonucleotide probes (wild-type and mutant-specific), and visualization of bound products with streptavidin-alkaline phosphatase and chromogenic substrates.

Subjects and clinical history data
We conducted a retrospective case series chart review of patients who tested positive for mutations in the MEFV gene at the UCLA Clinical Molecular Diagnostic Laboratory between February 2002 and February 2012. A total of 476 non-consanguineous subjects were reviewed. We followed the UCLA Office of Human Research Protection Program (OHRPP) data security in research guidance and procedures, coded all data during the study, and destroyed the coded data after the study. A total of 69 patient reviews were completed for positive double mutations and 83 patient reviews were completed for positive single mutation. Data were collected for: (i) ethnicity or ancestry, (ii) FMF type I or type II, (iii) presence or history of amyloidosis, (iv) early onset (<18 years of age), (v) time between chief complaint and testing, and (vi) patient follow-up after testing. A proband of Armenian ethnicity was defined as having one or both parents of Armenian descent.

Statistical analysis
Genetic mutations that were positive in less than five subjects are reported as descriptive statistics. Mutations that were seen in more than five subjects were grouped and analyzed by ethnicity, type I or type II, and early vs later onset. The genetic differences between the two groups were then compared using Pearson’s chi-squared test or Fisher’s exact test. Genotypes were also grouped as no mutation, compound heterozygous mutations, or homozygous mutation, and analyzed by ethnicity using the Cochran-Armitage trend test. All statistical analyses were performed with JMP (JMP Pro 7.0; SAS Institute Inc., Cary, NC), and a p-value of less than 0.05 was considered statistically significant.

Results
Armenian ancestry
During 10 years from February 2002 to February 2012, the UCLA Clinical Molecular Diagnostic Laboratory tested a total of 476 cases for suspected FMF by MEFV mutation testing. There were 69 double positive mutation cases (14.5%) and 83 single mutation cases
(17.4%). Of the 69 cases of double positive mutations, there were 34 cases of Armenian ethnicity (49.3%) and 35 cases of non-Armenian descent (50.7%). Of the 83 single mutation cases, there were 26 cases of Armenian ethnicity (31.3%) and 57 cases of non-Armenian ethnicity (68.7%).

**M694V double mutations**

Of the 34 cases of double positive mutation cases of Armenian ethnicity, 12 (35.3%) were M694V homozygotes and 22 (64.7%) compound heterozygotes, with 17 of the 22 (77.3%) having an M694V mutation as one of the two mutations. In contrast, out of the 35 cases of double mutation of non-Armenian ethnicity, there was only one (2.9%) M694V homozygote, while 34 (97.1%) were compound heterozygotes, with 16 of the 34 (47.1%) having an M694V mutation as one of the two mutations (Table 1). The difference in frequencies of the M694V homozygous mutation is highly significant between the two groups (p = 0.0006 by Fisher’s exact test, Fig. 1). The ethnicities were compared by analyzing for trend by genetic contribution of M694V (zero, one, or two copies). There was a significant trend of increasing genetic contribution of M694V mutation in Armenians by the Cochran-Armitage trend test ($P_{trend} < 0.0001$, Fig. 2). Conversely, in the non-Armenians, there was a significant trend of decreasing genetic contribution of M694V mutation ($P_{trend} < 0.0001$, Fig. 2).

Table 1. Double and single mutations

<table>
<thead>
<tr>
<th></th>
<th>Armenian</th>
<th>Non-Armenian</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Double mutations cases</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M694V homozygotes</td>
<td>12</td>
<td>1</td>
</tr>
<tr>
<td>Compound heterozygotes</td>
<td>17</td>
<td>16</td>
</tr>
<tr>
<td>V726A homozygotes</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Compound heterozygotes</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>E148Q homozygotes</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Compound heterozygotes</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>M680I (G/C) homozygotes</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Compound heterozygotes</td>
<td>13</td>
<td>7</td>
</tr>
<tr>
<td><strong>Single mutation cases</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive for mutation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M694V</td>
<td>16</td>
<td>10</td>
</tr>
<tr>
<td>E148Q</td>
<td>2</td>
<td>20</td>
</tr>
<tr>
<td>Negative for mutation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M694V</td>
<td>10</td>
<td>47</td>
</tr>
<tr>
<td>E148Q</td>
<td>24</td>
<td>37</td>
</tr>
</tbody>
</table>

* Percentages calculated out of 34 Armenian and 35 non-Armenian double mutation.
** Percentages calculated out of total number of cases for each mutation.

The M694V mutation in Armenian-Americans

Of the 83 single mutation cases, 26 cases were M694V single mutation (31.3%), 16 of which were of Armenian ethnicity (61.5%). In contrast, of the 57 cases without M694V mutation (68.7%), only 10 were of Armenian ethnicity (17.5%) and 47 were not (82.5%). Collectively, these data indicate a higher prevalence rate of M694V mutation in Armenians (p = 0.0001 by Pearson’s chi-squared test, Fig. 1).

Interestingly, MEFV gene mutations were also found in Asians with ancestry from the Far East, the
Indian subcontinent, and in admixed populations from the Philippines. There was one case of confirmed type I FMF with E148Q homozygous mutation of Chinese ancestry (parents from Hong Kong), three cases of suspected FMF with E148Q single mutation of Filipino/Chinese ancestry, and one case of confirmed FMF diagnosis with E148Q single mutation of Thai ancestry. There were two cases of E148Q/P369S compound heterozygote – one proband had a mother with Filipino ancestry and a father with English and Polish ancestry and the other has Hispanic parents. There were two cases of E148Q single mutation – one proband was from the Indian subcontinent and the other had Scottish and Irish ancestry.

**FMF type I vs type II**

In an attempt to correlate FMF type I or type II to specific mutations, a comprehensive chart review for each patient that tested positive was undertaken. Out of the 69 cases of double positive mutations, FMF type I or type II data was available for 30 cases (43.5%). There were only three cases of FMF type II documented (10%), and the remaining 27 cases were FMF type I (90%). Of the three FMF type II cases, two were M694V homozygotes, and one was M694V/M680I (G/C) compound heterozygote. All three FMF type II cases were of Armenian ethnicity. Of the 27 FMF type I cases, 18 were of Armenian ethnicity (66.6%). M694V homozygotes accounted for six cases (22.2%), of which all were of Armenian ethnicity.

**Early onset of disease**

Data were available for 41 of the 69 double positive mutations cases (59.4%) for early onset (defined as <18 years of age) of disease. Of these 41 cases, there were 31 cases of early onset disease (75.6%), 17 of whom were Armenians (54.8%). M694V homozygotes accounted for 7 of the 31 cases (22.6%) where data were available, and all 7 were Armenians. M694V/V726A compound heterozygotes accounted for 9 of the 31 cases (29.0%), 5 of whom were Armenians (55.6%). M694V/M680I (G/C) compound heterozygotes accounted for three additional cases, all of whom were Armenians. M694V/R761H, M694V/M694I, and M694V/E148Q compound heterozygous mutations each accounted for one case, and all three of these cases were Armenians.

**Renal amyloidosis**

Among the double positive mutations, there were four cases of documented renal amyloidosis, three of which had documented end stage renal disease and were status post kidney transplant at the time of data collection. The mutations for the renal amyloidosis cases were M694V homozygous (three cases) and M694V/M680I (G/C) compound heterozygous (one case). All three cases homozygous cases were of Armenian descent.

**Discussion**

In this study, we found that the M694V mutation is associated with an adverse FMF clinical outcome in the Armenian-American population, manifested by earlier onset of disease, severity of disease, and renal amyloidosis sequelae. Prior to 1989, the mode of FMF inheritance was unclear in Armenians, and a prospective study in families of 64 Armenian index cases from the UCLA FMF clinic was conducted (12). When the gene for FMF was found to be linked to the α-globin complex on chromosome 16p in both Armenians and non-Ashkenazi Jews by studying 14 Armenian and 9 non-Ashkenazi Jewish families with FMF, it was concluded that there was no evidence for locus heterogeneity (3). By sampling 65 Jewish, Armenian and Arab families and genotyping for eight markers from chromosome 16p, it was discovered that the FMF susceptibility gene was located within 0.305 cM of the D16S246 locus (4). It was observed through high-resolution mapping that there was significant allelic association for D16S2617 among Armenians and that a sizable minority of Armenian carriers appeared to be derived from the North African Jewish ancestral haplotype (6). By studying 56 families of different ethnicities (14 of which were Armenian), Shohat et al. identified 14 different MEFV core haplotypes and found significant association between amyloidosis and a specific haplotype, 153:104 bp, at markers D16S3370 and D16S2617 (17). In a later study of slightly larger size (83 families), Shohat et al. identified the M694V mutation as the particular mutation associated with amyloidosis (2). In our dataset of Armenian-Americans, we also found that the cases of documented renal amyloidosis, often associated with end-stage renal disease and status post kidney transplantation, were associated with the M694V mutation. In fact, in our population sample, we did not observe a single case of amyloidosis without an M694V variant. Not surprisingly, in every FMF type II case, the M694V variant was present. This M694V variant was also notable in FMF type I cases in the Armenians. Even though our sample size for affected East and South Asians was not large, it is interesting to note that the E148Q mutation was common throughout all cases identified, suggesting a historic founder mutation probably originating several centuries ago at the height of maritime trade between the Middle East and the Far East via the Indian subcontinent. It is also interesting to note that the time between initial chief complaint and date of testing is approximately 10 years. This implies that physicians are still missing this diagnosis frequently and patients with FMF are still suffering needlessly for lengthy periods of time. The advent of next-generation sequencing technologies and the gradual incorporation of this methodology into the clinical setting could benefit patients not only by potentially arriving at a definitive diagnosis sooner, but also by identifying other causative variants or modifier genes that may contribute to FMF.
Acknowledgements

This work was supported by National Institutes of Health F32 HL105036 Grant (F. S. O.) and Cedars-Sinai Medical Center Clinical and Translational Science Institute (CTSI) Clinical Scholars Award (F. S. O.). The CTSI was supported by the National Center for Research Resources, Grant UL1RR033176, and is now at the National Center for Advancing Translational Sciences, Grant UL1TR000124. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

References


The M694V mutation in Armenian-Americans